Back to search

National and Kapodistrian University of Athens

Η μεταβολή της ιντερλευκίνης 1α και των αγγειοκινητικών πεπτιδίων κατά την εξέλιξη της συστηματικής σκλήρυνσης

Abstract

dc:description

Increased concentrations of interleukin (IL)-1α have been recently described intissues of patients with systemic sclerosis (SSc), and this has been suggested to contribute to the pathogenesis of the disease. We conducted a double-blind, placebo -controlled study to assess the safety and efficacy of the fully humanized IL-1α blocking monoclonal antibody bermekimab in SSc. To evaluate response to treatment, we developed the score of inhibition of progression of SSc which was validated using the CRISS index and the modified CRISS index. The primary endpoint was met in 80% of bermekimab-treated patients vs 20% of placebo-treated patients (p: 0.023). Most of efficacy was found for the decrease of lung diffusion capacity. Bermekimab is a promising new candidate that could be efficacious in the treatment of SSc. Treatment with bermekimab was associated with monocyte modulation of cytokine production and attenuation of platelet activation.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Solomonidi, Nikolitsa
  • Σολομωνίδη, Νικολίτσα

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/55189

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Solomonidi, Nikolitsa; Σολομωνίδη, Νικολίτσα. Η μεταβολή της ιντερλευκίνης 1α και των αγγειοκινητικών πεπτιδίων κατά την εξέλιξη της συστηματικής σκλήρυνσης. National and Kapodistrian University of Athens, 2023. http://hdl.handle.net/10442/hedi/55189